Haluk Tezcan, MD, Oncology, Palo Alto, CA


Oncology Palo Alto, CA

Breast Cancer, Cancer Genetics/Cancer Risk Assessment, Genitourinary Oncology, Hematologic Oncology

Chief Medical Officer Adjunct Clinical Assistant Professor

Dr. Tezcan is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Tezcan's full profile

Already have an account?

Education & Training

  • Roswell Park Cancer InstituteFellowship, 1995
  • University of Nebraska Medical Center
    University of Nebraska Medical CenterResidency, Internal Medicine, 1992
  • Istanbul University Faculty of Medicine
    Istanbul University Faculty of MedicineClass of 1986

Certifications & Licensure

  • OR State Medical License
    OR State Medical License 2020 - 2021
  • MO State Medical License
    MO State Medical License 2019 - 2022
  • NE State Medical License
    NE State Medical License 2019 - 2022
  • CA State Medical License
    CA State Medical License 2012 - 2022
  • ID State Medical License
    ID State Medical License 1995 - 2021
  • WA State Medical License
    WA State Medical License 1992 - 2022
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012
  • Holmes Award Idaho Women’s Health, 2005
  • Evelyn Martin Memorial Fellowship 1988
  • Join now to see all

Clinical Trials

Publications & Presentations


Journal Articles

  • Validation of the 12-Gene Colon Cancer Recurrence Score as a Predictor of Recurrence Risk in Stage II and III Rectal Cancer Patient  
    Marlies S. Reimers MS, Kuppen PJK, Lee M, Lopatin M, Tezcan H, Putter H, Clark-Langone K, Liefers GJ, Shak S, and  van de Velde CJH, JNCI J Natl Cancer Inst , 1/1/2014
  • Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from A...  
    Bendell JC, Bekaii-Saab TS, Cohn AL, Hurwitz HI, Kozloff M, Tezcan H, Roach N, Mun Y, Fish S, Flick ED, Dalal D, Grothey A, Oncologist, 1/1/2012
  • DNA Methylation in Lung Cancer  
    Tezcan H, NEJM, 1/1/2008
  • Join now to see all

Books/Book Chapters


  • The 12-gene colon cancer assay: summary of clinical evidence
    Burke E, Tezcan H, Lopatin M, Clark-Langone K, Lee M, Shak S, Sing A, ASCO GI Symposium, 1/1/2014
  • Prospective evaluation of a 12-gene assay on patient treatment decisions and physician confidence in mismatch repair-proficient (MMR-P) stage IIa colon cancer patients
    Alberts SR, Renfro LA, Lopatin M, Tezcan H, Sloan J, Chao C, Lee M, ASCO GI Symposium, 1/1/2014
  • Global quantitative measures using next-generation sequencing for breast cancer presence outperform individual tumor markets in plasma
    Beasley EM, Abramson RD, Alexander GE, Chan D, Bradley K, Collin F, Crager M, Dei Rossi A, Dorado J, Friedman A, Gibb WJ, Jeong J, Jones C, Ku CJ, Ma Y, Morlan J, Qu K..., SABCS, 1/1/2014
  • Join now to see all

Press Mentions

  • Lexent Bio Announces Use of Its Liquid Biopsy Assay, Confera Dx, in a Peer-Reviewed Paper Published in the Journal Molecular Cancer Therapeutics
    Lexent Bio Announces Use of Its Liquid Biopsy Assay, Confera Dx, in a Peer-Reviewed Paper Published in the Journal Molecular Cancer TherapeuticsMay 14th, 2020
  • Liquid Biopsies Intensify Surveillance of ctDNA
    Liquid Biopsies Intensify Surveillance of ctDNASeptember 3rd, 2019

Professional Memberships

Other Languages

  • German, Turkish

Industry Relationships

  • Vice President of Oncology, CounsylNew Product DevelopmentDisclosure: I am an employee of Counsyl2015 - Present